We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Accord-UK Ltd have informed us that important safety warnings for the excipient Propylene glycol are missing from the patient information leaflet (PIL).
As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of...
Medac Pharma LLP is recalling specific batches of products due to some inspected vials showing hairline damage to the shoulder of the vials. This is a second alert for further batches identified.
The CMA has imposed over £100 million in fines after Advanz inflated the price of thyroid tablets, causing the NHS and patients to lose out.
Caution is required if prescribing febuxostat in patients with pre-existing major cardiovascular disease, particularly, in those with evidence of high urate crystal and tophi burden or those initiating urate-lowering therapy.
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 16 February 2021.
The CMA has accepted legally binding commitments from Essential Pharma to continue supplying a key bipolar drug at an affordable price for at least 5 years.
The CMA is consulting on proposed commitments from Essential Pharma to keep a key bipolar drug on the market, and ensure it is affordable to the NHS.
The CMA has fined firms over £35 million for an illegal arrangement in the supply of important NHS prescription anti-nausea tablets.
A joint enforcement notice warns all organisations offering Kenalog as a hayfever treatment to stop advertising it on social media or website advertising
The world’s most innovative treatments for COVID-19 will soon be fast-tracked through the UK’s clinical trial system, as the government announces funding for the most promising treatments.
First published during the 2019 to 2022 Johnson Conservative government
The CMA has issued decisions imposing fines on suppliers of nortriptyline tablets for breaching competition law.
Health supplements boss who failed to rein in aggressive overseas call centre banned for nine years.
The CMA has opened an investigation into suspected anti-competitive practices in the supply of drugs used to treat bipolar disorder.
Employment Tribunal decision.
Decisions made by The MHRA following investigations into complaints about advertising for licensed medicines.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).